Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Coya Therapeutics, Inc. (NASDAQ: COYA ) is a US biotech working on neurodegenerative and autoimmune using T cell [Treg] modulation. Their main candidates are COYA 302 and COYA 301. COYA 302 is probably the most promising today, and it’s intended for multiple indicationsMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a grad ...